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Progression to symptomatic disease in people infected
with HIV›1 in rural Uganda: prospective cohort study
Dilys Morgan, Cedric Mahe, Billy Mayanja, James A G Whitworth
Abstract
Objectives To estimate the rate of progression from
seroconversion to symptomatic disease in adults
infected with HIV›1, and to establish whether the
background level of signs and symptoms commonly
associated with HIV›1 in uninfected controls are likely
to affect progression rates.
Design Longitudinal, prospective cohort study of
people infected with HIV›1 and randomly selected
subjects negative for HIV›1 antibodies identified
during population studies.
Setting Study clinic with basic medical care in rural
Uganda.
Subjects 275 patients infected with HIV›1 (107
prevalent cases and 168 incident cases) and 246
controls negative for HIV›1 antibodies.
Main outcome measures Signs and symptoms of
HIV disease, as determined by stages 2 and 3 of the
World Health Organization clinical staging system.
Results The median time from seroconversion to
WHO stage 2 was 25.4 months and to stage 3 was
45.5 months. 43% of the participants infected with
HIV›1 had signs or symptoms by two years after
seroconversion. The most common clinical conditions
used to define progression of disease were weight loss,
mucocutaneous manifestations, bacterial infections,
chronic fever, and chronic diarrhoea. Although the
rates of these conditions (apart from minor weight
loss) were significantly higher in the participants
infected with HIV›1, they were also relatively frequent
in the control group. Herpes zoster, oral candidiasis,
and pulmonary tuberculosis were not common events
in the control group and therefore were more
indicative of infection with HIV›1.
Conclusions Disease progression associated with
infection with HIV›1 seems to be rapid in rural
Uganda. This is most likely due to the high prevalence
of conditions in the general population that could be
taken as symptoms and signs of infection with HIV›1.
Introduction
Although some studies have found that progression of
disease in patients infected with HIV›1 is more rapid in
African people living in sub›Saharan Africa,1–4 most
studies have found rates of progression similar to those
in rich countries.5–9 However, in Africa it is rare to find
cohorts for whom tests negative for HIV›1 antibody
and positive HIV›1 tests (and hence an estimated date
of seroconversion) are documented.
We report rates of, and reasons for progression to,
early symptomatic disease in adults for whom
estimated dates of HIV›1 seroconversion were avail›
able in a cohort in rural Uganda. We also assessed the
rates of conditions commonly associated with HIV›1
infection in participants infected with HIV›1 before
they developed AIDS compared with those in
participants not infected with HIV›1.
Methods
Participants and design
We established a clinical cohort in rural south western
Uganda in 1990 by recruiting participants from a large
study that followed the dynamics of HIV›1 infection
with annual HIV›1 serosurveys of the general popula›
tion.10 The cohort comprised prevalent cases of HIV›1
infection diagnosed in 1989 and 1990 and incident
cases detected during annual serosurveys; we used ran›
domly selected people who were negative for HIV›1
antibodies, as controls.11 The estimated date of
seroconversion for the incident cases was taken as the
midpoint between the last test negative result and first
positive result for antibodies to HIV›1.
All participants gave informed written consent
(signature or thumbprint), and they were reviewed by a
study doctor every three months. The participants were
asked about their medical history, were given a full
physical examination, and underwent basic laboratory
investigations. Any complaints or medical findings
were investigated and treated with drugs from the
World Health Organization’s list of essential drugs.
Participants could also attend the clinic at any time
when they were ill during the study. At each routine
visit, participants infected with HIV›1 were categorised
according to the clinical and performance scale of the
staging system for patients infected with HIV›1
proposed by the WHO (see box).12
The staff at the clinic were not aware of the HIV
status of the participants. This ensured confidentiality
and reduced the risk of bias in the reports. All partici›
pants were strongly encouraged to attend the HIV
counselling sessions and testing facilities that were
provided as part of the study.
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Statistical analysis
To minimise the number of missed events when the
median time from seroconversion to symptomatic dis›
ease, represented by WHO stages 2 and 3, was
estimated, we included only incident cases seen within
two years of their estimated date of seroconversion.
The WHO staging system is hierarchical—it is assumed
that once individuals have moved to a given stage, they
have passed though all previous stages. Participants
who had symptoms at enrolment or who progressed
directly to a higher stage were considered to be left
censored (the event that defined the move to the next
stage happened before the date of recording). This left
censoring tends to overestimates of the time from
seroconversion to a given stage. We provide the
proportion of individuals who were left censored for
each stage so that the degree of bias can be assessed.
The date of the routine appointment at which a
participant was first seen with an event that defined a
WHO stage was used to estimate the time between
seroconversion and the patient developing symptoms.
Kaplan›Meier survival methods were used to
estimate the median probabilities (and interquartile
ranges) and cumulative probabilities (95% confidence
intervals by Greenwood’s method) for times to the
various endpoints. To estimate the background level of
stage defining conditions in this population, we
compared the rates of conditions during follow
up—from the first visit to the last visit before the patient
was classified as having AIDS—for all incident cases,
prevalent cases and controls by using the Mantel›
Haenszel test. All analyses were performed with the
STATA 6.0 statistical package. This paper reports data
from 1990 to the end of 2000.
Results
By the end of 2000, 275 patients infected with HIV›1
(107 prevalent cases and 168 incident cases) and 246
controls who tested negative for HIV›1 infection had
been enrolled. We enrolled more than 80% of
individuals identified for selection from the large
population study into the clinical cohort, and over 92%
of participants living in the area were seen during
2000. Compliance rates remained high.
In total, 142 incident cases were seen within two
years of their estimated date of seroconversion (table
1). Figure 1 shows the cumulative probabilities of
remaining symptom free after seroconversion.
The most common clinical conditions associated
with disease progression were weight loss, mucocuta›
neous manifestations, bacterial infections, chronic
Proposed WHO staging system for patients infected with HIV›112
Stage 1:
• Asymptomatic
• Persistent generalised lymphadenopathy
Stage 2:
• Weight loss between 5% and 10% of body weight
• Minor mucocutaneous manifestations (seborrhoeic dermatitis, prurigo,
fungal nail infections, recurrent oral ulcerations, angular stomatitis)
• Herpes zoster within the past five years
• Recurrent upper respiratory tract infections (for example, bacterial
sinusitis)
And/or
• Performance scale 2: symptomatic, normal activity
Stage 3:
• Weight loss > 10% body weight
• Unexplained chronic diarrhoea for longer than one month
• Unexplained prolonged fever (intermittent or constant) for longer than
one month
• Oral candidiasis
• Oral hairy leukoplakia
• Pulmonary tuberculosis within last year
• Severe bacterial infections (for example, pneumonia, pyomyositis)
And/or
• Performance scale 3: bedridden for less than 50% of the day during the
last month
Clinical stage 4 (AIDS):
• HIV wasting syndrome*
• Pneumocystis carinii pneumonia
• Toxoplasmosis of the brain
• Cryptosporidiosis with diarrhoea for more than one month
• Cryptococcus, extrapulmonary
• Cytomegalovirus infection of an organ other than liver, spleen, or lymph
nodes
• Herpes simplex virus infection—mucocutaneous for more than 1 month
or visceral of any duration
• Progressive multifocal leukoencephalopathy
• Any disseminated endemic mycosis
• Candidiasis of the oesophagus, trachea, bronchi, or lungs
• Atypical mycobacteriosis, disseminated
• Non›typhoidal salmonella septicaemia
• Extrapulmonary tuberculosis
• Lymphoma
• Kaposi’s sarcoma
• HIV encephalopathy†
And/or
• Performance scale 4: bedridden for more than 50% of the day during last
month
*Defined by the Centers for Disease Control and Prevention as weight loss of greater
than 10% body weight, plus either unexplained chronic diarrhoea (greater than 1
month) or chronic weakness and unexplained prolonged fever (greater than 1 month).
†Defined by the Centers for Disease Control and Prevention as clinical findings of
disabling cognitive dysfunction and/or motor dysfunction, interfering with activities of
daily living, progressing over weeks to months in the absence of a concurrent illness or
condition other than infection with HIV that could explain the findings.
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fever, and chronic diarrhoea (table 1). The number of
events and the rates of these and other conditions
defining a WHO stage (prior to AIDS) in all
participants are shown in table 2. With the exception of
minor weight loss, the rates of these conditions were
significantly higher in participants infected with HIV›1
than in controls, although the conditions were also
relatively frequent in the control group. Herpes zoster,
oral candidiasis, and pulmonary tuberculosis were not
common events in the control participants, as shown
by their higher rate ratios.
Discussion
Early manifestations and progression rates of disease
in patients infected with HIV›1 are particularly difficult
to assess in Africa. Most reports of clinical manifesta›
tions have been in patients admitted to hospital or
attending clinics; these patients are not representative
of the general population, because patients tend to
present late and few make it to referral centres.
Time between seroconversion and appearance of
symptoms
Symptoms of infection with HIV›1 seem to developed
quickly in incident cases seen within two years of their
estimated date of seroconversion: only 17% of
participants remained symptom›free five years after
seroconversion. The median time to WHO stage 2 (25.4
months) was probably overestimated due to the effects
of left censoring, but the bias for time to WHO stage 3
(45.5 months) should be negligible. Other studies in
Kenya and Haiti have also reported rapid progression
from seroconversion to symptomatic disease.13 14 Pro›
gression times in industrialised countries are much
longer, with 78%›85% of patients infected with HIV
remaining asymptomatic five years after sero›
conversion.15 16
Recognising progression to symptomatic disease
The most common single reason for recognising pro›
gression to symptomatic disease in our cohort was
minor weight loss, but this was as common in controls
who tested negative for HIV›1 antibodies as in partici›
pants infected with HIV›1. Minor mucocutaneous
problems, severe bacterial infections, chronic fever, and
chronic diarrhoea were also common clinical com›
plaints that occurred before a patient was classified as
having AIDS. Although participants infected with
HIV›1 had significantly higher rates of these condi›
tions, they were also frequent in the controls (see table
2). However, in agreement with other African
studies,17 18 we found that herpes zoster, oral candidia›
Table 1 Enrolment characteristics of the incident cases infected with HIV›1, used for
estimating progression times, median time from seroconversion to WHO stages 2 and 3
and reasons for progression
Characteristic Value
No of participants seen within two years of seroconversion 142
Men 70
Women 72
Median (IQR) age (years) 30 (24›38)
Median (IQR) time between tests negative and positive for HIV antibodies (months) 12.1 (9.8›18.0)
Median (IQR) time from seroconversion to enrolment (months) 10.6 (7.3›16.8)
Median (IQR) follow up from seroconversion to last visit (years) 4.2 (2.3›6.6)
No of patients in each WHO stage on enrolment:
1 (asymptomatic) 123
2 (mild disease) 12
3 (moderate disease) 6
4 (AIDS) 1
Median (95% CI) time from seroconversion to stage 2 (months)* 25.4 (23.9 to 29.6)
No (%) of patients in WHO stage 2 63
Reasons for progression:**
Minor weight loss (5›10% baseline weight) 38 (61)
Minor mucocutaneous manifestations 16 (25)
Herpes zoster 9 (14)
Median (95% CI) time from seroconversion to stage 3 (months)† 45.5 (36.2 to 51.3)
No (%) of patients in WHO stage 3 72
Reasons for progression:**
Major weight loss (>10%) 24 (33)
Severe bacterial infection 23 (32)
Chronic diarrhoea 13 (18)
Chronic fever 10 (14)
Pulmonary tuberculosis 3 (4)
Oral candidiasis 2 (3)
Oral hairy leukoplakia 1 (1)
IQR=interquartile range.
*Using 104 subjects in stage 2: 51 progressed from stage 1; 12 were in stage 2 and 7 were in higher
stages on enrolment; and 34 went straight to stages 3 or 4. Thus 53 (51%) were left censored.
**Each participant could have more than one reason for progression.
†Using 80 subjects in stage 3: 66 progressed from stages 1 or 2; 6 in stage 3 and 1 in stage 4 on
enrolment; and 7 went straight to stage 4. Thus 14 (18%) were left censored.
Table 2 Rates of visits to study clinic by patients with conditions defining WHO stages (pre›AIDS) in participants infected with HIV›1
compared with controls negative for HIV›1 antibodies
Infected with HIV
(total PYO=1120.2)
Negative for HIV antibodies
(total PYO=1336.5)
Rate ratio* (95% CI) P value†
No of
patients
Rate (per 100
PYO)
No of
patients
Rate (per
100 PYO)
WHO stage 2:
Weight loss (5%›10%) 521 46.5 551 41.2 1.1 (1.0 to 1.3) 0.045
Minor mucocutaneous disease 197 17.6 58 4.3 4.1 (3.0 to 5.4) <0.001
Herpes zoster 51 4.6 6 0.5 10.1 (4.4 to 28.9) <0.001
Recurrent upper respiratory tract infection 21 1.9 7 0.5 3.6 (1.5 to 8.4) 0.002
WHO stage 3:
Weight loss >10% 232 20.7 98 7.3 2.8 (2.2 to 3.6) <0.001
Chronic diarrhoea 60 5.4 22 1.6 3.3 (2.0 to 5.3) <0.001
Prolonged fever 56 5.0 37 2.8 1.8 (1.2 to 2.7) 0.005
Oral candidiasis 43 3.8 1 0.08 51.3 (7.1 to 372) <0.001
Oral hairy leukoplakia 6 0.5 1 0.08 7.2 (0.9 to 59.5) 0.033
Pulmonary tuberculosis 24 2.1 2 0.08 28.6 (3.9 to 212) <0.001
Severe bacterial infection 126 11.3 47 3.5 3.2 (2.3 to 4.5) <0.001
PYO=person years of observation.
*Rate in patients infected with HIV›1 divided by rate in participants negative for HIV›1 antibodies.
†Comparison of rate ratios using Mantel›Haenszel test.
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sis, and pulmonary tuberculosis were highly predictive
for infection with HIV›1. The small number of partici›
pants may have affected our results, but a study of
women in Rwanda reported similar rates of weight
loss, mucocutaneous conditions, chronic fever, and
diarrhoea in groups whose test results were positive
and negative for HIV›1 antibodies.6 In rich countries,
the rates of these conditions, and the rate ratios, were
considerably lower in groups testing positive and
negative for HIV›1 antibodies.19 20
Background levels of other conditions
Most of the population in rural Uganda lives in
poverty; food is often in limited supply, there is no
electricity, and there is poor access to any, let alone
clean, water. Malaria is endemic, and infections other
than HIV, especially bacterial infections, are common.
The shorter interval from seroconversion to sympto›
matic disease in African populations probably reflects
the high background level of these conditions, rather
than rapid disease progression.
Conclusions
The progression of disease in patients infected with
HIV›1 in Africa seems to be rapid; this is most likely to
be due to the high prevalence of what could be taken as
symptoms and signs of infection with HIV›1 in the
general population. Studies that showed rapid progres›
sion of disease in patients infected with HIV in Africa
could have led to the belief that HIV disease progresses
more rapidly in Africa than elsewhere.
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What is already known on this topic
The few studies that have reported time from
seroconversion to HIV›1 symptomatic disease in
poor countries suggest that this interval is shorter
than in rich countries
What this study adds
Progression from seroconversion to symptomatic
disease seems to be rapid in rural Africa
The apparent rapid disease progression in rural
Africa is most likely to be due to the high
prevalence of what could be taken as symptoms
and signs of HIV›1 in the general population
Endpiece
The danger of health books
Be careful of reading health books, you may die of
a misprint.
Mark Twain
Submitted by Peter Teichman, assistant professor,
Department of Family Medicine, West Virginia
University
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Commentary: Virus, host, or environment?
Peter H Kilmarx
Morgan et al present data from a fruitful, long running
body of research that looked at the clinical manifesta›
tions of infection with HIV›1 in a cohort in rural
Uganda. Their key finding was that symptoms sugges›
tive of infection with HIV›1 develop relatively rapidly—
the median time from seroconversion to symptomatic
disease (WHO stage 2) was only 25.4 months. In
contrast, most patients in rich countries are asympto›
matic even five years after acquiring infection.
Does disease associated with infection with HIV›1
progress more quickly in African populations? This is a
crucial issue. Knowing the rate of disease progression
allows us to give a prognosis to individual patients. At
the population level, it helps us to understand the
broader impact of the epidemic on population
characteristics, the workforce, and healthcare needs.
Rates of disease progression might differ between popu›
lations for three reasons: variations in the pathogenicity
of the subtypes of HIV›1 that cause infections, variations
in host characteristics, and the presence or absence of
certain environmental factors—such as the presence of
coexistent Mycobacterium tuberculosis or the availability of
adequate medical treatment. These factors are difficult to
disentangle, but in developed countries, rates of disease
progression do not seem to be associated with the viral
subtype or the patient’s country of origin.1 Data from
poor countries are sparse and conflicting, but some
show that the progression of disease in these settings is
more rapid than in rich parts of the world.2 3 More
recently, the use of highly active antiretroviral drugs has
become the overwhelming factor that has affected
disease progression. In 2001 the estimated number of
deaths from HIV and AIDS in North America, western
Europe, Australia, and New Zealand was 75 500 (out of
a total population of about 731 million); this compares
with 2.3 million deaths in sub›Saharan Africa (total
population about 596 million).4
This report from Morgan et al indicates a key rea›
son for the apparently rapid development of
symptoms in people in rural Uganda: many of the
study’s participants who were negative for HIV›1 anti›
bodies also had symptoms suggestive of infection with
HIV›1. The most commonly reported condition—loss
of 5›10% of body weight—occurred at a rate of more
than 40 per 100 person years of follow up whether or
not participants were infected with HIV›1. Other
symptoms, such as prolonged fever, were more
common in the people infected with HIV›1, but they
were also common among those who were negative for
HIV›1 antibodies. The rapid development of symp›
toms among rural Ugandans infected with HIV›1 is, at
least in part, unrelated to infection, but it is linked to
the poor background health status of this population.
This study underscores two points. Firstly, the pres›
ence of symptoms is a poor guide for staging disease
associated with HIV›1 infection. “Harder” outcomes,
such as CD4 T lymphocyte count, blood concentration
of HIV RNA, and death, are better endpoints on which
to base epidemiological studies of disease progression.
However, these laboratory tests are expensive and not
available for patients in poor settings. Accurate, low
cost assays to monitor disease activity and progression
are needed urgently.5 Secondly, the health status of
rural Africans is generally poor. Further research is
needed to determine the role of the environment in
the progression of disease associated with infection
with HIV›1 in poor settings. Meanwhile, it is appropri›
ate that initiatives to provide antiretroviral treatment,
which are much needed, also aim to improve basic
health care and control other infectious diseases, such
as malaria and tuberculosis.
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One hundred years ago
Is the lady doctor a failure?
This question has recently been asked in America and in one
important quarter at least has been answered in the affirmative.
This is all the more remarkable, since America is not only the
country which witnessed the new birth of the lady doctor in
modern times, but that in which she has hitherto appeared most
to flourish. Miss Elizabeth Blackwell, who was the first, graduated
in 1849. Three years later there were six in Philadelphia. In 1889
there were 3,000 lady doctors in the United States; in 1896 there
were 4,555, and now there are probably 6,000, some of whom
have very lucrative practices. But these would seem to be the
exception. From Chicago comes the news that Princess Bamha
Dhuleep Singh, daughter of the late Maharajah Dhuleep Singh,
and seventy other young women, who were studying medicine at
the North›Western University, will have to seek another school.
After thirty two years’ trial the trustees of the University have
come to the conclusion that women are not a success as doctors.
The school is to be abolished and the property sold. One of the
trustees, Mr. Raymond, goes so far as to say that it is impossible to
make a doctor of a woman, He adds: “We have run the Women’s
Medical School at a loss of £5,000 a year. Women cannot grasp
chemical laboratory work or the intricacies of surgery. Fifteen
years ago the graduating class of men and women signed a
memorial saying that coeducation was a failure. Then we
conducted the college exclusively for women, and it has been
worse than a failure.”
(BMJ 1902;i:287)
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